Cite
HARVARD Citation
Cluzeau, T. et al. (2021). Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). Journal of clinical oncology. 39 (14), pp. 1575-1583. [Online].